Last month, the Food and Drug Administration authorized genetic-testing company 23andMe to provide the first ever direct-to-consumer genetic test for cancer risk. The test screens for three types of mutations on the BRCA-1 and BRCA-2 genes, which are two genes found to be associated with risk for ovarian and breast cancer. 23andMe’s $199 test kit … Continue reading Women shouldn’t have to resort to second-rate options for comprehensive healthcare